(a)In this section, “opioid antagonist” means:
(1)naloxone hydrochloride; or
(2)any other similarly acting and equally safe drug approved by the federal Food and Drug Administration for the treatment of a drug overdose.
(b)(1) This section applies to:
(i)insurers and nonprofit health service plans that provide coverage for prescription drugs under individual, group, or blanket health insurance policies or contracts that are issued or delivered in the State; and
(ii)health maintenance organizations that provide coverage for prescription drugs under individual or group contracts that are issued or delivered in the State.
(2)An insurer, a nonprofit health service plan, or a health maintenance organization
Free access — add to your briefcase to read the full text and ask questions with AI
(a) In this section, “opioid antagonist” means:
(1) naloxone hydrochloride; or
(2) any other similarly acting and equally safe drug approved by the federal Food and Drug Administration for the treatment of a drug overdose.
(b) (1) This section applies to:
(i) insurers and nonprofit health service plans that provide coverage for prescription drugs under individual, group, or blanket health insurance policies or contracts that are issued or delivered in the State; and
(ii) health maintenance organizations that provide coverage for prescription drugs under individual or group contracts that are issued or delivered in the State.
(2) An insurer, a nonprofit health service plan, or a health maintenance organization that provides coverage for prescription drugs through a pharmacy benefits manager is subject to the requirements of this section.
(c) An entity subject to this section that includes on its formulary an opioid antagonist may apply a prior authorization requirement for an opioid antagonist only if the entity provides coverage for at least one formulation of the opioid antagonist without a prior authorization requirement.